LIL-HM2B4-100μg / 询价
LIL-HM2B4-500μg / 询价
LIL-HM2B4-500μgx2 / 询价
Human LILRB4/CD85k/ILT3 Protein
Recombinant Human LILRB4/CD85k/ILT3 Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Gln22-Arg256 [Accession | AAH26309].
The protein has a predicted MW of 52.6 kDa. Due to glycosylation, the protein migrates to 60-68 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human LILRB4 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human LILRB4 is greater than 95% as determined by SEC-HPLC.
Immobilized Human LILRB4, hFc Tag at 1μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-LILRB4 Antibody, hFc Tag with the EC50 of 27.3ng/ml determined by ELISA (QC Test).
Human LILRB4, hFc Tag captured on CM5 Chip via Protein A can bind Human APOE 4, His Tag with an affinity constant of 74.20 nM as determined in SPR assay (Biacore T200).
LILRB4,also known as CD85k and LIR-5, ILT3, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation. Mature human ILT3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM).LILRB4 is receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles.
HM18; ILT3; ILT-3; LILRB4; LIR5; CD85K
(1)Samuel J , Heyu C , Mi D , et al. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML[J]. Molecular Therapy, 2018:S1525001618303721-.
